Mechanistic basis of post-treatment control of SIV after anti-[alpha]4[beta]7 antibody therapy

Treating macaques with an anti-[alpha]4[beta]7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS computational biology 2021-06, Vol.17 (6)
Hauptverfasser: Wells, Chad R, Cao, Youfang, Durham, David P, Byrareddy, Siddappa N, Ansari, Aftab A, Ruddle, Nancy H, Townsend, Jeffrey P, Galvani, Alison P, Perelson, Alan S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treating macaques with an anti-[alpha]4[beta]7 antibody under the umbrella of combination antiretroviral therapy (cART) during early SIV infection can lead to viral remission, with viral loads maintained at < 50 SIV RNA copies/ml after removal of all treatment in a subset of animals. Depletion of CD8.sup.+ lymphocytes in controllers resulted in transient recrudescence of viremia, suggesting that the combination of cART and anti-[alpha]4[beta]7 antibody treatment led to a state where ongoing immune responses kept the virus undetectable in the absence of treatment. A previous mathematical model of HIV infection and cART incorporates immune effector cell responses and exhibits the property of two different viral load set-points. While the lower set-point could correspond to the attainment of long-term viral remission, attaining the higher set-point may be the result of viral rebound. Here we expand that model to include possible mechanisms of action of an anti-[alpha]4[beta]7 antibody operating in these treated animals. We show that the model can fit the longitudinal viral load data from both IgG control and anti-[alpha]4[beta]7 antibody treated macaques, suggesting explanations for the viral control associated with cART and an anti-[alpha]4[beta]7 antibody treatment. This effective perturbation to the virus-host interaction can also explain observations in other nonhuman primate experiments in which cART and immunotherapy have led to post-treatment control or resetting of the viral load set-point. Interestingly, because the viral kinetics in the various treated animals differed-some animals exhibited large fluctuations in viral load after cART cessation-the model suggests that anti-[alpha]4[beta]7 treatment could act by different primary mechanisms in different animals and still lead to post-treatment viral control. This outcome is nonetheless in accordance with a model with two stable viral load set-points, in which therapy can perturb the system from one set-point to a lower one through different biological mechanisms.
ISSN:1553-734X
1553-7358
DOI:10.1371/journal.pcbi.1009031